A Phase 1 interventional study of SRP-9004 in Limb Girdle Muscular Dystrophy and Limb Girdle Muscular Dystrophy Type 2D/R3, sponsored by Sarepta Therapeutics, Inc.. Terminated at 2 sites in United States. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Sarepta Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States — 3 open to participants now, 9 under way, 1 of them phase 3. Muscular Dystrophies, Limb-Girdle · United States.
Among the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States, this one is the 14th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 in phase 1, and was the 29th registered.
47 studies on the registry are indexed under Muscular Dystrophies, Limb-Girdle; 10 are open to participants now.
Browse Muscular Dystrophies, Limb-Girdle studies →3 of the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States are open now. Recruiting first, the newest first:
Virginia Commonwealth University · Sites in United States
Ages 6–50
Cure CMD · Sites in United States
Boston Children's Hospital · Sites in United States
Ages 1 wk–100 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Muscular Dystrophies, Limb-Girdle studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.
This study: 4 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 8 · Phase 3 4
First in 2002; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 13 across 22 interventional studies indexed under Muscular Dystrophies, Limb-Girdle.
Median enrollment 11 across the 17 interventional studies, 101 across the 13 observational. Of the 18 that completed or were terminated, 5 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 30 have an industry lead sponsor. The 10 most frequent:
Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
Sarepta Therapeutics, Inc. has 9 studies filed under Muscular Dystrophies, Limb-Girdle — fewer than ten, so there is no comparison to draw.
1 of the studies in Muscular Dystrophies, Limb-Girdle with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00390104Boston Children's HospitalMolecular Analysis of Patients With Neuromuscular Disease | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the safety of SRP-9004.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of SRP-9004 on Day 1.
Drug: SRP-9004
Intravenous (IV) infusion.
Number of Participants with Treatment-emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESI) and Treatment-emergent Serious Adverse Events (SAEs)
Time frame: Up to 60 months
Change from Baseline Through Day 60 in Quantity of Alpha-sarcoglycan (α-SG) Protein Expression
Time frame: Baseline, Day 60
Change from Baseline Through Month 24 in Quantity of α-SG Protein Expression
Time frame: Baseline, Month 24
Change from Baseline Through Month 60 in North Star Assessment for Dysferlinopathy (NSAD) Total Score
Time frame: Baseline, Month 60
Change from Baseline Through Month 60 in Performance of the Upper Limb (PUL) Version 2.0 Total Score
Time frame: Baseline, Month 60
Change from Baseline Through Month 60 in Time to Rise From Floor
Time frame: Baseline, Month 60
Change from Baseline Through Month 60 in Time to Ascend 4 Steps
Time frame: Baseline, Month 60
Change from Baseline Through Month 60 in Time to Complete 10-meter Walk/Run (10MWR)
Time frame: Baseline, Month 60
Change from Baseline Through Month 60 in Time to Complete 100-meter Walk/Run (100MWR)
Time frame: Baseline, Month 60
Change from Baseline through Month 60 in Creatine Kinase (CK) Level
Time frame: Baseline, Month 60
Time to Change of Disease Milestones (Loss of Ambulation)
Time frame: Baseline, Month 60
Change from Baseline Through Month 60 in Skeletal Muscle Magnetic Resonance Imagining (MRI) Findings
Time frame: Baseline, Month 60
Change from Baseline Through Month 60 in Wearable Device Stride Velocity 95% (SV95C) (Ambulatory Participants Only)
Time frame: Baseline, Month 60
Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by Forced Vital Capacity (FVC)
Time frame: Baseline, Month 60
Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by FVC Percentage (%) Predicted
Time frame: Baseline, Month 60
Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by Forced Expiratory Volume in 1 Second (FEV1)
Time frame: Baseline, Month 60
Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by FEV1 % Predicted
Time frame: Baseline, Month 60
Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by Peak Expiratory Flow Rate (PEFR)
Time frame: Baseline, Month 60
Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by Maximal Inspiratory Pressure (MIP)
Time frame: Baseline, Month 60
Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by Maximal Expiratory Pressure (MEP)
Time frame: Baseline, Month 60
Ran from Jan 2025 to primary completion in Jun 2025, 5 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophies, Limb-Girdle →